However, compared with the PD-1 involved subgroup (Figure 4(e)), the participation of chemotherapy significantly increased the risk of rash in the PD-L1 subgroup (p=0.03) [63, 77, 80, 96]. This evidence concerns the gene PDCD1 and exanthem.